Makena’s Accelerated Approval Will Hang In Balance At US FDA Panel Meeting In October

 
• By Sue Sutter
Pregnant_Woman
Whether Makena should continue to be marketed for preventing preterm birth is the focus of an October AdComm. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers